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ABSTRACT
Background Most cancers in sub- Saharan Africa (SSA) 
are diagnosed at advanced stages, with limited treatment 
options and poor outcomes. Part of this may be linked to 
various events occurring in patients’ journey to diagnosis. 
Using the model of pathways to treatment, we examined 
the evidence regarding the routes to cancer diagnosis in 
SSA.
Design and settings A systematic review of available 
literature was performed.
Methods The Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses guidelines were followed. 
Between 30 September and 30 November 2019, 
seven electronic databases were searched using 
terms relating to SSA countries, cancer and routes to 
diagnosis comprising the population, exposure and 
outcomes, respectively. Citation lists of included studies 
were manually searched to identify relevant studies. 
Furthermore, ProQuest Dissertations & Theses Global was 
searched to identify appropriate grey literature on the 
subject.
Results 18 of 5083 references identified met the 
inclusion criteria: eight focused on breast cancer; 
three focused on cervical cancer; two each focused on 
lymphoma, Kaposi’s sarcoma and childhood cancers; 
and one focused on colorectal cancer. With the exception 
of Kaposi’s sarcoma, definitive diagnoses were made in 
tertiary healthcare centres, including teaching and regional 
hospitals. The majority of participants initially consulted 
within primary care, although a considerable proportion 
first used complementary medicine before seeking 
conventional medical help. The quality of included studies 
was a major concern, but their findings provided important 
insight into the pathways to cancer diagnosis in the region.
Conclusion The proportion of patients who initially use 
complementary medicine in their cancer journey may 
explain a fraction of advanced- stage diagnosis and poor 
survival of cancer in SSA. However, further research 
would be necessary to fully understand the exact role (or 
activities) of primary care and alternative care providers in 
patient cancer journeys.
BACKGROUND
Sub- Saharan Africa (SSA) is overburdened 
with communicable diseases, while the inci-
dence and mortality from non- communicable 
diseases such as cancer are rising across the 
region.1 The increase in cancer incidence 
is associated with poor control of cancer- 
related infections and unhealthy lifestyle 
choices, which may be addressed, in part, by 
implementing effective public health inter-
ventions.2–6 Mortality from cancer is strongly 
associated with stage at diagnosis; early- 
stage cancers enable treatment with curative 
intent and better prognoses than late- stage 
diseases.7–9 Most cancers in SSA are diagnosed 
at advanced stages due to late presentation 
of symptoms, weak referral mechanisms and 
limited diagnostic capacity.8–10 Early- stage 
cancers and precancerous lesions are detect-
able by screening asymptomatic patients, but 
this is limited to few sites and is very rarely 
used in SSA. Therefore, interventions aimed 
at promoting early symptomatic presenta-
tion and expedited diagnosis are likely to 
yield better cancer outcomes in the region. 
However, such interventions must be rooted 
in empirical evidence to ensure effectiveness 
and to maximise local resources use.
The model of pathways to treatment offers 
a useful framework to examine the routes to 
diagnosis of symptomatic cancer.11 It describes 
five possible events in the pathways to treat-
ment: detection of bodily changes, perceived 
reasons to seek medical help, first consulta-
tion with a healthcare provider, diagnosis and 
start of treatment.11 Numerous studies have 
explored these events in cancer, but only a 
few have specifically investigated patients’ 
Strengths and limitations of this study
 ► This is the first systematic review of the evidence 
relating to the routes to diagnosis of cancer in Sub- 
Saharan Africa (SSA).
 ► The search strategies, assessment of quality and 
narrative synthesis followed good practice.
 ► Selected studies used small sample sizes and sys-
tematically introduced biases in the selection of par-
ticipants and data collection.
 ► However, their findings provide unique insights into 
patients’ journey to cancer diagnosis in SSA.
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initial contact with healthcare providers in SSA.12 Using 
this framework, we investigated patients’ routes to cancer 
diagnosis in SSA, focusing on the initial point of consulta-
tion and eventual diagnosis. Identifying and categorising 
the routes to diagnosis may explain advanced- stage 
cancers and provide the basis for early diagnosis interven-
tions in the region.
METHODS
A systematic narrative review was performed. The conduct 
and reporting of the review was based on the Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
(PRISMA) framework (see online supplemental file 1).13
Search strategy
Between 30 September and 30 November 2019, a 
systematic search of the following electronic databases 
was performed: Ovid MEDLINE(R) ALL (1946–30 
September 2019), Embase (1974–30 September 2019), 
Web of Science (1915 (1)–2019 (69)), PsycINFO (1806–
week 2 of September 2019), CINAHL Complete, Global 
Health (1973–week 36 2019) and African Journals Online. 
The search strategy included terms, their synonyms and 
Medical Subject Headings terms relating to SSA countries, 
cancer and routes to diagnosis; comprising the popu-
lation, exposure and outcomes, respectively (table 1). 
Online supplemental file 2 shows the search strategy in 
MEDLINE, PsycINFO, Embase and Global Health. Cita-
tion lists of included studies were manually searched to 
identify relevant studies. Furthermore, ProQuest Disser-
tations & Theses Global was searched to identify appro-
priate grey literature on the subject.
Eligibility criteria
Included studies investigated cancer diagnosis, described 
the routes or the patient’s pathway to diagnosis (including 
the settings of initial consultation and definitive diagnosis) 
and were conducted in 1 or more of the 48 SSA countries. 
The list of SSA countries matches those featured on the 
World Bank data catalogue used to describe health and 
socioeconomic indices in the region.14 Excluded studies 
were non- English studies, focused on populations outside 
the region of SSA, investigated diseases other than cancer, 
cancer treatment, outcomes and attitudes toward cancer 
diagnoses. All study designs (qualitative and quantitative) 
were eligible for inclusion.
Study selection
This involved a two- stage screening process. First, title, 
abstract and full articles of potentially eligible studies 
were sequentially screened by an experienced researcher 
(TM) against the inclusion and exclusion criteria. Conse-
quently, studies that appeared to meet the inclusion 
criteria or where a decision could not be made based on 
the title and/or abstract were selected for full- text review 
to identify those for the final analysis.
Data extraction and synthesis
One reviewer (TM) extracted data from all included 
studies. Extracted data were added to a data extraction 
spreadsheet, which was initially piloted with seven studies. 
Data extraction included study characteristics: country of 
study, design, participants’ characteristics, cancer type, 
healthcare settings for initial consultation and eventual 
diagnosis. Quantitative synthesis was not possible because 
our final selection differed in terms of cancer sites and 
Table 1 Search terms
Population Exposure Outcome
Terms relating sub- Saharan Countries
Angola, Gabon, Nigeria, Benin, Gambia, 
The Rwanda, Botswana, Ghana, São 
Tomé and Principe, Burkina Faso, 
Guinea, Senegal, Burundi, Guinea- 
Bissau, Seychelles, Cabo Verde, Kenya, 
Sierra Leone, Cameroon, Lesotho, 
Somalia, Central African Republic, 
Liberia, South Africa, Chad
Madagascar, South Sudan, Comoros, 
Malawi, Sudan, Congo, Dem. Rep., Mali, 
Swaziland, Congo Rep., Mauritania, 
Tanzania, Côte d'Ivoire, Mauritius, 
Togo, Equatorial Guinea, Mozambique, 
Uganda, Eritrea, Namibia, Zambia, 
Ethiopia, Niger, Zimbabwe
Terms relating to cancer
Cancer, Neoplasm, Malignant Neoplasm, 
tumour, Malignant tumour, Astrocytoma, 
Adenocarcinoma, Glioma, Mesothelioma, 
Medulloblastoma, Myeloma, Melanoma, 
Neuroblastoma, Sarcoma, Nonmelanoma, 
Osteosarcoma, Teratoma, Seminoma, 
Hodgkin, Leukaemia, Lymphoma, 
Retinoblastoma
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outcome measures. For instance, some studies described 
patients initially presenting to ‘healthcare practitioner’, a 
term that may be used to describe primary care physicians 
or doctors in secondary care. Therefore, we performed a 
narrative synthesis using the framework of Rodgers and 
colleagues.15 Participants’ characteristics and the study’s 
main findings are illustrated in tables and figures.
Quality assessment
Three reviewers (TM, WH and SWDM) assessed the meth-
odological quality of eligible studies using the Newcastle- 
Ottawa Quality Assessment Scale (NOS) for cohort, NOS 
adapted for cross- sectional studies,16 17 and the Joanna 
Briggs Institute (JBI) Critical Appraisal Checklist for Qual-
itative Research.18 TM and SWDM independently selected 
the appropriate checklist based on study design. The 
cohort and cross- sectional studies were awarded stars and 
rated ‘good’, ‘satisfactory’ or ‘poor quality’, depending on 
the extent to which they meet the NOS checklist criteria 
on the three main domains: selection, comparability and 
outcomes alongside associated statistics. Good- quality 
studies were awarded four stars in the selection domain, 
and two stars in each of the comparability and outcome 
domains. Studies rated satisfactory were awarded two 
stars in the selection domain, one star in comparability 
domain, and up to three stars in the outcome domain. 
Poor- quality studies were awarded zero star in the compa-
rability domain, and one star in the selection or outcome 
domains. The JBI checklist is not a scoring system but a 
useful tool for evaluating the risk of bias in the design and 
conduct of qualitative studies. The checklist consists of 10 
criteria with four possible responses: ‘yes,’ ‘no,’ ‘unclear’ 
and ‘inapplicable.’ Each qualitative study was evaluated 
against the checklist criteria. Discrepancies between the 
reviewers were resolved by consensus, although no study 
was excluded based on quality.
Patient and public involvement




The search identified 5083 articles. After screening title 
and abstract and removing duplicates, 4933 irrelevant 
articles were excluded: 150 full- text articles were assessed 
with 18 meeting the inclusion criteria. A PRISMA flow-
chart showing the reasons for abstract and full article 
exclusions is shown in figure 1. The 18 studies recruited a 
total of 4871 participants from nine SSA countries, 70% of 
which were females with the average age ranging from 4 to 
59 years. The characteristics of included studies are illus-
trated in table 2, with the results of quality assessment in 
table 3. Seven of the studies were conducted in Nigeria,19–25 
three in Ethiopia,26–28 two each in Ghana29 30 and South 
Africa,31 32 and one each in Cameroon,33 Tanzania34 and 
Kenya.35 The final study involved five countries (Kenya, 
Uganda, Malawi, Cameroon and Nigeria).36
All 18 studies were observational with 7 cross- sectional 
surveys, 7 cohorts (using medical records), 3 qualitative 
(face- to- face interviews) and a mixed- methods study (using 
both qualitative and quantitative data). Eight studies 
examined breast cancer19–22 26 27 29 30; three focused on 
cervical cancer23 28 34; two each focused on lymphoma,32 33 
Kaposi’s sarcoma31 36 and childhood cancers25 35; and one 
Figure 1 Flowchart of the study selection process. SSA, sub- Saharan Africa.
copyright.
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focused on colorectal cancer.24 None of the 18 studies 
specifically investigated the routes to cancer diagnosis, 
although 15 studies reported the settings of initial consul-
tation after symptom onset. The remaining three studies 
recruited participants from primary care- based HIV 
clinics to investigate Kaposi’s sarcoma and lymphoma 
diagnoses.31 32 36 These studies were included in our final 
selection, given that both cancer types are significantly 
more common in patients with HIV and that patients with 
HIV are mostly seen at such settings.
Assessment of study quality
Overall, none of the qualitative studies fulfilled the JBI 
checklist criteria, and none of the quantitative studies 
could be classified as ‘good quality’ due to the limita-
tions in their methodology (table 3). The main limita-
tions of these studies pertained to their small sample 
sizes, biases in participant recruitment and data collec-
tion strategies. The sample sizes in most of the cohort 
and cross- sectional studies were rather small to be repre-
sentative of the target population. Four- fifth of included 
studies recruited participants from tertiary healthcare 
centres, thereby introducing selection bias by systemati-
cally excluding patients diagnosed or treated elsewhere. 
In some studies, surveys and face- to- face interviews were 
performed by nurses or physician–researchers from the 
hospitals where participants were undergoing treatment, 
thus drawing possibly desirable responses. Additionally, 
statistical analyses were largely descriptive, with most 
studies presenting percentages only. Despite these limits, 
however, the studies provided some important findings 
relevant to the aim of our review, thereby warranting their 
inclusion in the synthesis.
Routes to cancer diagnosis
Across the eight studies on breast cancer, providers in 
tertiary healthcare centres made the definitive diagnoses 
in all cases (table 2).19–22 26 27 29 30 After noticing symp-
toms, participants initially consulted the physicians (in 
primary or secondary care), used complementary medi-
cine (including traditional healers, herbalists and prayer 
centres) or presented directly to the hospital. The propor-
tion of patients using each of these routes to diagnosis 
differed slightly between studies but very similar across all 
the eight studies.19–22 26 27 29 30 On average, around a third of 
the participants—across the studies—initially presented 
with symptoms to each of the physician, complementary 
medicine practitioners or directly to the hospital.
In two of the three studies focused on cervical cancer, 
participants presented with symptoms directly to tertiary 
health centres where cervical cancer diagnoses were 
confirmed (table 2).23 28 Conversely, 47% of the partic-
ipants in the third study initially presented symptoms 
to traditional healthcare practitioners before returning 
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In a survey of 82 patients with rectal bleeding and 
colorectal cancer, Alatise et al found that only 39% of 
the participants had consulted a physician, with 38% 
of participants opting to use herbs before going to the 
doctors (table 2).24
Of 6292 HIV- infected patients enrolled at an HIV clinic, 
Chu et al31 found 3% diagnosed with Kaposi’s sarcoma 
within 7 years of routine HIV care. Similarly, healthcare 
providers from 33 HIV clinics across five African coun-
tries diagnosed 1328 HIV patients with Kaposi’s sarcoma 
during 4 years of routine HIV care.36 In both studies, 
providers at the HIV clinics detected Kaposi’s sarcomas 
during routine examination for opportunistic infections.
Two studies surveyed parents and carers of children 
with childhood cancers to determine causes of diagnostic 
delay. In one study, 59% of parents initially sought comple-
mentary medicine for their children, although about 60% 
later consulted in primary care, 38% in secondary care 
and 2% presented directly to tertiary care.35 In contrast, 
69% of parents in the second study initially sought conven-
tional medical help, but 24% either self- medicated, used 
herbalist services or presented to a church.25
In a survey of parents and carers of children with 
Burkitt lymphoma, Afungchwi and colleagues showed 
that 55% had used traditional healers before hospital 
admission, with 42% using this service before reporting 
to primary care.33 In contrast, all 163 patients diagnosed 
with Hodgkin and non- Hodgkin's lymphoma in Antel et 
al’s32 study were referred to the specialist by healthcare 
practitioners.32
DISCUSSION
The route to diagnosis is a strong predictor of cancer 
outcomes.37 38 In this review, we examined the evidence 
relating to cancer diagnosis in SSA. Across all selected 
studies, definitive diagnoses of cancer were made by 
specialists in large tertiary healthcare centres, except 
for Kaposi’s sarcomas, which were diagnosed at various 
primary care- based specialist clinics. However, partici-
pants’ journeys to the specialist clinics are often indirect, 
with a considerable proportion initially using comple-
mentary medicine before consulting conventional 
medical services.
Strengths and limitations
To our knowledge, this is the first systematic review of 
the evidence regarding the routes to cancer diagnosis 
in SSA. Our rigorous search strategy and explicit inclu-
sion/exclusion criteria, quality assessment of included 
studies, and narrative synthesis followed good practice. 
Our search identified only a modest number of studies, a 
third of which were conducted in Nigeria, the most popu-
lous country with the largest economy in the region. We 
omitted non- English studies as these may include studies 
published in French, Portuguese and other African 
languages. While the decision to omit these studies may 
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have no reason to believe that such omission had any 
impact on our findings.
About half of our final selection focused on breast 
cancer, reducing the scope of the review. The studies 
also had small sample sizes, which limits the interpreta-
tion and generalisability of our findings. Additionally, 
the majority recruited participants and gathered data 
(using researcher- administered questionnaires) from the 
hospital facilities where patients were being treated for 
their cancers, typically in the tertiary healthcare centres. 
This is not surprising, given the weak primary care and 
limited cancer registries in SSA, thus limiting the quality 
and quantity of data available for research. However, 
recruiting participants from tertiary health centres 
systematically exclude patients treated in private hospi-
tals and those whose cancers may never be found due to 
affordability or comorbidity. Furthermore, gathering data 
from the hospital using physician- administered question-
naires may generate more socially desirable responses. In 
this case, it is likely that participants under- report their 
use of complementary medicine and self- medication to 
look good in the eyes of their providers, who may be part 
of the research team.
Finally, publication bias is possible as some studies on 
the subject may have failed to be published in reputable 
peer- reviewed journals, and so would have been omitted 
from the databases searched for this review.
Interpretation of findings
The pathways to diagnosis of symptomatic cancer involves 
a series of events, beginning with the patient noticing 
a bodily change and deciding to seek medical help.11 
Definitive diagnosis requires biopsy of affected tissue by 
specialists in secondary or tertiary healthcare settings. In 
high- income countries like the UK and Denmark, most 
patients with cancer initially present with symptoms to 
primary care, with a smaller proportion presenting to 
secondary care as emergencies.37 Primary care physicians 
in these countries play a key role in selecting those whose 
symptoms warrant specialist investigations using prelim-
inary test results and clinical guidelines.39 Healthcare 
services in many SSA countries are pluralistic, comprising 
a three- tier system: primary care (including dispensa-
ries, health centres and private clinics); secondary care 
(including private, mission and district hospitals); and 
tertiary healthcare.26 The tertiary healthcare centres are 
referral centres with various subspecialties and are the 
main setting for definitive diagnosis of cancer.26 28 30 40 
However, the role of primary care in SSA is not always well 
defined, with several unorthodox providers, including 
traditional healers and faith clinics, offering similar 
services, although unqualified to diagnose cancer or to 
refer patients for specialist investigations.9 41–43 Patients 
in these countries may present with symptoms directly 
to tertiary healthcare centres, regardless of the nature 
or duration of symptoms. They may also be referred by 
physicians in primary or secondary care, but often with 
no standardised referral pathways or mechanism to 
ensure continuity of care.9 41–43 This problem is further 
compounded by frequent long distances to healthcare 
centres and out- of- pocket payments, particularly for 
patients in rural and socioeconomically deprived areas 
who may resort to complementary medicine instead.
Indeed, a considerable proportion of participants in 
this review initially used complementary medicine before 
consulting in primary care, with some also presenting 
directly to the hospital. Only a third of women with breast 
cancer initially reported symptoms to primary care, 
despite widespread awareness campaign with relatively 
easy to spot symptoms.44 45 Fifty- three per cent of patients 
with cervical cancer symptoms, 39% of those with rectal 
bleeding and around two- thirds of childhood cancers 
initially sought help in primary care. Access to conven-
tional healthcare is restricted in most SSA countries due 
to limited availability and affordability.9 42 46 47 In their 
respective cancer journey, patients in this region may 
start with or revert to complementary medicine, which is 
considered cheaper and more natural, with some prac-
titioners offering complete cure of cancer rather than 
possible remission offered by conventional medicine.26 41 
The use of complementary medicine is widespread in 
SSA, although evidence suggests that the practitioners 
can misdiagnose cancer, resulting in advanced- stage diag-
nosis and reduced chances of survival.33 48
The findings of this review may have been influenced 
by the level of bias in included studies: in which case, our 
report on the proportion using various routes to diagnosis 
will be inaccurate. If at all, we may have overestimated 
the proportion of patients consulting in primary care or 
underestimated those using complementary medicine 
before diagnosis, given the lack of public awareness of 
cancer and weakness of healthcare systems in the region, 
with significant underdiagnoses.
CONCLUSION
Recent data from SSA suggest a rapid increase in the risk 
and deaths from major cancer types. In a region where 
infectious diseases persist, with limited healthcare budgets 
and shortages of specialists, urgent solutions are required 
to minimise the burden of cancer on its rapidly growing 
and ageing population. The majority of participants in 
our selected studies initially presented symptoms to 
primary care, though the proportion first using comple-
mentary medicine is considerable. This latter group of 
patients constitutes a major source of concern, bearing in 
mind that complementary medicine practitioners in SSA 
are likely to be unequipped to spot cancer or to make a 
specialist referral when necessary.
However, there is a need for further research to fully 
understand patients’ pathways to cancer diagnosis in SSA. 
For instance, our review found that the majority of patients 
initially presented in primary care, but we are uncertain 
on the exact roles this played in their journey to diag-
nosis. As such, a comprehensive research programme to 
examine the role of primary care and alternative care in 
copyright.
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cancer diagnosis is recommended as this may contribute 
to the development of possible diagnostic guidelines.
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